Patients with type 2 diabetes who suffer with hyperglycemia and dyslipidemia that is treated with antidiabetic and antidislipidemia, it will be very meaningful if there is a drug that can overcome the conditions of hyperglycemia, dyslipidemia, as well as lowering the risk of complications. Currently, the development trend of antidiabetic drugs in the world, leading to the development of dual agonists PPARα/γ. To optimize the utilization, we develop the manufacturing of nutmeg seed extract as an antidiabetic and antidislipidemik nutraceutical dual agonists PPARα/γ, with proper dosage formulation technology and meet the quality standards. For commercialization extract, requires completeness of data validation and pre-clinical data as well as the data of clinical trials of manufactured product that can be utilized by the public. This study has been carried out the validation process to extract nutmeg, caplet formulation Glucopala™, acute toxicity test and test activities Glucopala™ caplet manufacturing output by PT. Kimia Farma. Through the validation of the extraction process, the extract obtained free myristicin nutmeg and safrole. In the acute toxicity test results, it is known that Glucopala™ caplets included categories are not toxic to the test animals. Results antidiabetic activity test and antidislipidemi show that Glucopala™ caplets pilot scale manufacturing output has antidiabetic activity and antidislipidemi characterized by a decrease in fasting blood glucose and triglyceride levels in rats with type 2 diabetes mellitus after administration Glucopala™ caplets. The events are significantly different from group negative controls were given PGA 2% with α of 0.05 and did not differ significantly from the positive control group given the drug fenofibrate with the pioglitazone-α 0.05.